This trial is evaluating whether MRD-BMT with Fludarabine-based RIC for Acquired AA will improve 3 primary outcomes and 2 secondary outcomes in patients with Anemia, Aplastic. Measurement will happen over the course of Up to 100 days post transplant.
This trial requires 25 total participants across 3 different treatment groups
This trial involves 3 different treatments. MRD-BMT With Fludarabine-based RIC For Acquired AA is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are in Phase < 1 and are in the first stage of evaluation with people.
"This group summarizes the current state of knowledge regarding anemia and its impact on pediatric patients. In most respects, it provides clinicians with an unbiased overview of current evidence." - Anonymous Online Contributor
"Anemic and aplastic anemias could be potentially cured with appropriate treatment and can be achieved at one third of the cost of the regular blood transfusion treatment. All patients receiving blood need to be fully informed about these possible positive results and the risks of the transfusion treatment." - Anonymous Online Contributor
"Around 40 million Americans have anemia, aplastic anemia each year; however it is difficult to obtain accurate prevalence estimates of both conditions since they are often not reported to health care providers." - Anonymous Online Contributor
"Mild symptoms of anemia or aplastic include loss of appetite and fatigue, and more severe manifestations of anemia or aplastic include a decrease in hemoglobin values, peripheral neuropathy, and anemia-related symptoms. If symptoms are not addressed and treated promptly, anemia or aplastic may evolve into a life-threatening condition." - Anonymous Online Contributor
"Iron deficiency and low transferrin can be treated with oral iron supplementation but there is no specific treatment for anemia as a result of chronic blood loss." - Anonymous Online Contributor
"Both hemoglobinopathies and other causes of anemia can cause anemia. Aplastic anemia can develop after bone marrow suppression, often due to cancer therapy. Hematopathologic examination demonstrates a reduction in circulating blood cells, as measured by their reduced surface area. These alterations are not readily reversible in most patients and usually require treatment with blood transfusions." - Anonymous Online Contributor
"Clinical trials of therapy for anemia should include patients with low Hct and Apl < or = 15% at baseline. Clinical trials for aplastic patients should include patients with Apl > or = 10% or low Hct at baseline. Randomized trials may be of use for anemic and aplastic patients but, for anemic patients, they may have a greater risk of producing misleading results if Hct is the only outcome measure used." - Anonymous Online Contributor
"The data obtained from HES and Hb can be used to anticipate hemoglobin level response to iron therapy; however, Hb and HES values cannot predict response to erythropoietin therapy for anemia and aplastic anemia." - Anonymous Online Contributor
"The following are the present-day guidelines for the use of aFludarabine-based treatments for acute leukemia in the adult population. For those patients who do not achieve a complete remission, maintenance chemotherapy is recommended. For those patients who reach a complete remission, aFludarabine-based treatment lasting longer than 8 cycles is recommended." - Anonymous Online Contributor
"The average age someone gets anemia, aplastic in a population without prior history of the disorder were 10-23 and 48-64+ years respectively. The average duration of the disorder in someone with aplastic anemia and iron deficiency anemia was 9-31+ and 11-55+ years respectively." - Anonymous Online Contributor
"This new combination of fludarabine with the anthracycline-derived antibiotic mrd-bmt is safe and effective for Aa-associated disease. The long-term benefits of treatment should be investigated in a larger study." - Anonymous Online Contributor
"This is the first study to reveal significant clinical benefits of fd + brt/ric in a subset of individuals with AA who responded well to the aforementioned drugs and has suggested a novel drug-therapy combination in AA that warrants further investigation." - Anonymous Online Contributor